The impact of SCYL1 expression to survival data was evaluated using the PrognoScan database, we found high expression of SCYL1 was associated with worsened prognoses in breast cancer patients as measured by overall survival (OS), disease special survival (DSS), and relapse free survival (RFS) (Figure 3). Here, SCYL1 is linked to breast carcinoma.